Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the Mineralis second quarter 2025 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the former presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. It is now my pleasure to introduce your host, Dan Ferry of LifeSci Advisors. Thank you. You may begin. Thank you, Operator. I would like to welcome everyone joining us today for our second quarter 2025 conference call. Earlier this afternoon, we issued a press release providing our second quarter 2025 financial results and business updates. A replay of today's call will be available on the investor section of our website, approximately one hour after its completion. After our prepared remarks, we will open the call for Q&A. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in today's press release and our SEC filings, including our annual report on Form 10-K and subsequent filings. Please note that these forward-looking statements reflect our opinions only as of today, August 12, 2025. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. I would now like to turn the call over to John Cobleton, Chief Executive Officer of Mineralis Therapeutics. Thank you, Dan. Good afternoon, everyone, and welcome to our second quarter...